Ticagrelor (Brilinta) has been promoted for years as a breakthrough in coronary heart care, producing billions in gross sales and incomes high placement in therapy pointers the world over. It was positioned as a safer, simpler choice than older blood thinners, and its status gave docs purpose to prescribe it broadly.
The issue is that the muse supporting this drug was by no means strong. From the start, questions on information reliability and trial integrity adopted it. As a substitute of solutions, sufferers and docs got a story of superiority that has not held up underneath nearer inspection.
In the event you or somebody near you has been prescribed this drug, you must know its status as a number one therapy is constructed on shaky floor. When flaws within the science form prescribing patterns, the dangers fall squarely on the individuals taking the drugs. That’s why it’s vital to look at how this drug earned approval within the first place, what later investigations uncovered, and what safer paths ahead appear to be for sufferers right now.
FDA Scientists Warned Ticagrelor Was Much less Protected Than Marketed
An in-depth investigation revealed in The BMJ revealed that the blockbuster anticlotting drug ticagrelor was accepted over the sturdy objections of U.S. Meals and Drug Administration (FDA) medical reviewers who warned the trial information was unreliable.1 The approval hinged on the PLATO trial — the large examine that secured ticagrelor’s worldwide approval, which enrolled 18,624 sufferers throughout 43 international locations.
Whereas the revealed outcomes claimed a discount in cardiovascular deaths, coronary heart assaults, and strokes, U.S. sufferers truly fared worse on ticagrelor in comparison with clopidogrel (Plavix). This raised critical questions on whether or not the advantages touted by ticagrelor’s maker AstraZeneca had been actual or manufactured.
• U.S. sufferers had worse outcomes — The FDA’s evaluation revealed that sufferers within the U.S. had a 27% larger threat of main cardiovascular occasions when given ticagrelor, the precise reverse of what was seen in Europe and different areas. AstraZeneca argued that top aspirin doses within the U.S. defined this distinction, however FDA scientists rejected that clarification as inadequate.
This issues to you as a result of for those who had been prescribed ticagrelor within the U.S., the very inhabitants the place the drug carried out poorly, your threat of hurt might be larger than your physician realizes.
• Lead FDA reviewer sounded the alarm — Dr. Thomas Marciniak, a medical officer on the FDA recognized for his rigorous opinions, concluded in a 47-page memo that ticagrelor appeared inferior in each security and efficacy. He described AstraZeneca’s submission as “the worst in my expertise relating to completeness of the submissions and the sponsor responding utterly and precisely to requests.”
His advice was to disclaim approval. Regardless of this, FDA management accepted the drug. This implies the inexperienced gentle got here not from consensus amongst scientists however from administrative override.
• Knowledge monitoring raised crimson flags — One other alarming element from the investigation was that AstraZeneca monitored most trial websites themselves, besides in 4 international locations the place impartial organizations oversaw the method. In these 4 independently monitored international locations — together with the U.S. — ticagrelor carried out worse than clopidogrel.
The place the sponsor oversaw information assortment, ticagrelor appeared superior. This inconsistency means that oversight and information dealing with instantly formed the reported outcomes, which ought to concern you for those who belief that “gold normal” trials are all the time neutral.
• Loss of life information had been altered — The BMJ uncovered that adjudicators — these tasked with classifying affected person outcomes — added 45 coronary heart assaults to the clopidogrel group and nil to the ticagrelor group. Moreover, amongst disputed deaths, the ultimate classifications disproportionately favored ticagrelor.
Much more troubling, The New England Journal of Medication publication reported 905 deaths, whereas AstraZeneca’s inner information listed 983, leaving dozens unaccounted for.2 In the event you depend on revealed medical journals to mirror actuality, this discrepancy exhibits how information manipulation formed the drug’s picture.
• Mechanism of hurt tied to bleeding and misclassified occasions — The trial design used a major endpoint that mixed demise from vascular causes, coronary heart assault, or stroke. This meant even small shifts in how occasions had been labeled might tip the scales.
When deaths or coronary heart assaults had been reclassified in ticagrelor’s favor, the looks of profit emerged. For you, this demonstrates how consequence definitions — not simply biology — decide whether or not a drug is labeled a “life saver” or a “dangerous wager.”
What you’re taking from this isn’t nearly ticagrelor however in regards to the system itself. If a multibillion-dollar drug might be accepted over scientific objections, it exhibits how vital it’s so that you can ask questions, take a look at alternate options, and demand transparency in how medical information is reported. Empowering your self with this data means you’re not blindly depending on medicine that had been fast-tracked via a flawed course of.
Key Platelet Research Have been Riddled with Errors
The unique BMJ investigation uncovered main information integrity issues within the PLATO trial, casting doubt on whether or not the drug actually provided a bonus over cheaper rivals.3 Now, with generic variations set to hit the market, a follow-up investigation revealed in The BMJ has gone additional by analyzing two smaller platelet research that AstraZeneca used to defend ticagrelor’s effectiveness in acute coronary syndrome — ONSET/OFFSET and RESPOND.4
• Research had been inaccurately reported, casting critical doubt on AstraZeneca’s claims — These trials had been central to convincing regulators and docs that ticagrelor labored higher, but the first endpoint outcomes had been misstated in Circulation, a number one cardiology journal.5,6 This implies the very basis used to justify the drug’s “superiority” over cheaper choices was constructed on flaws.
• Individuals confronted excessive and weird calls for — Sufferers in these platelet research, who had steady coronary artery illness, had been required to provide giant quantities of blood — as much as 604 milliliters throughout visits, which is greater than a full unit donated at a blood financial institution. Usually, platelet research contain only one or two blood attracts, however AstraZeneca’s required six inside a single eight-hour interval.
As one trial investigator admitted, solely probably the most dedicated individuals might endure that burden. This uncommon setup raises questions on whether or not the info mirrored typical sufferers or solely these prepared to bear intense procedures, which instantly impacts whether or not the outcomes apply to actual life.
• Knowledge gaps and lacking information weakened credibility — The BMJ investigation discovered that greater than 60 platelet readings had been lacking from the datasets submitted to the FDA. Even worse, among the excluded outcomes confirmed considerably larger platelet exercise, suggesting ticagrelor didn’t inhibit clotting as strongly as marketed.
Implausible readings, similar to platelet exercise growing after therapy, had been included in closing analyses, however as a substitute of being flagged, they had been hidden via unpublished “information changes.” In the event you trusted these revealed outcomes to mirror actuality, the findings present that key information was both mishandled or ignored.
• Authorship was misrepresented — A number of people listed as examine authors later denied involvement, whereas others who actively recruited sufferers had been excluded. For instance, Tonny Nielsen, recognized as a Danish investigator and writer, said outright, “I didn’t take part within the RESPOND examine.” Conversely, a Baltimore doctor who enrolled 12 sufferers wasn’t credited.
Even the Research Strategies Launched Bias
Platelet aggregation, the lab take a look at used to measure clotting, is notoriously delicate to timing and method. Consultants informed The BMJ that such exams are finest performed at a single website to make sure consistency, but AstraZeneca unfold them throughout 10 websites in a number of international locations.7
The investigation couldn’t verify whether or not all employees acquired correct coaching, growing the possibility of inconsistent outcomes. This issues to your security as a result of if platelet perform was measured improperly, the claims about ticagrelor’s effectiveness lose validity.
• Statistical tips distorted outcomes — RESPOND initially confirmed non-significant outcomes, which means ticagrelor didn’t reliably outperform clopidogrel. However by altering the definition of the first endpoint, the revealed paper reported it as important. That single shift turned ticagrelor right into a “winner.” In the event you had been ever informed this drug had clear benefits, the reality is these benefits had been manufactured by re-writing the principles of research.
• What this implies to your well being choices — Victor Serebruany, a Johns Hopkins pharmacologist and considered one of ticagrelor’s earliest critics, summarized it bluntly: “If docs had recognized what occurred in these trials, they’d by no means have began utilizing ticagrelor.”8
Which means that the belief positioned in ticagrelor’s science was misplaced, and medicines like clopidogrel had been pushed apart based mostly on defective proof. Armed with this data, you’ll be able to ask sharper questions on whether or not the drugs you’re provided are backed by strong science — or by manipulated information.
Learn how to Shield Your self from Flawed Drug Approvals
The reality about ticagrelor’s approval course of is unsettling. When a drug is pushed via regardless of critical doubts about security and effectiveness, you’re left susceptible. However you’re not powerless right here. Your well being is determined by taking energetic steps to know the dangers, select safer choices, and keep away from turning into depending on remedies constructed on weak or manipulated science.
In the event you’ve been prescribed an anticlotting drug after a coronary heart process, or for those who’re caring for a liked one in that place, these steps offer you a transparent approach to transfer ahead.
1. Query the power of the proof — Earlier than beginning any drug, look into whether or not the important thing research supporting it had issues with information accuracy, lacking data, or conflicting outcomes. On this case, ticagrelor’s research had been riddled with errors and misreporting. If you ask “What does the proof truly present?” you set your self up for higher choices.
2. Cut back your threat by addressing root causes — Anticlotting medicine are sometimes prescribed due to lifestyle-driven coronary heart illness. In the event you decrease your threat via weight loss plan, motion, and decreasing poisonous exposures, you’ll rely much less on medicine within the first place.
Lower vegetable oils out of your weight loss plan, keep away from ultraprocessed meals, improve your consumption of whole-food carbohydrates, and construct power via day by day strolling and common resistance coaching. This improves your circulation and lowers clotting threat naturally.
3. Observe your progress with the correct markers — As a substitute of counting on outdated measures like complete ldl cholesterol, concentrate on well being exams that really mirror your metabolic well being. Monitor your HOMA-IR rating to trace insulin resistance, verify fasting glucose, and control your triglyceride-to-HDL ratio.
It’s also possible to use a easy blood stress cuff at residence to look at for enhancements in circulation. Deal with these numbers like checkpoints — each enchancment is proof that your day by day decisions are shifting you in the correct path and away from dependence on dangerous medicine.
4. Keep knowledgeable and proactive about drug security — Don’t assume that simply because a drug is FDA-approved, it’s your best option. Ticagrelor proves that approvals typically ignore critical flaws. Learn investigations, comply with updates from impartial researchers, and ask your self whether or not the advantages outweigh the dangers. Information places you in cost, not the system.
By making these strikes, you’re taking again the management that was stripped away when flawed medicine had been pushed into the system. Your well being outcomes turn out to be much less about pharmaceutical income and extra about what truly works to your physique.
FAQs In regards to the Anticlotting Drug Ticagrelor
Q: What’s ticagrelor and why is it prescribed?
A: Ticagrelor, bought as Brilinta, is an anticlotting drug broadly prescribed for sufferers with acute coronary syndrome, which incorporates coronary heart assaults and unstable chest ache. It was marketed as superior to clopidogrel, an older and cheaper drug, based mostly on scientific trial information that’s now underneath critical scrutiny.
Q: Why are specialists questioning the approval of ticagrelor?
A: The FDA’s personal medical reviewers warned that ticagrelor carried out worse than clopidogrel in U.S. sufferers and flagged main information high quality points within the landmark PLATO trial. Regardless of these warnings, FDA management accepted the drug. Later investigations discovered lacking information, altered demise information, and inconsistencies that each one favored ticagrelor.
Q: What new issues had been uncovered in follow-up research?
A: A 2025 BMJ investigation revealed that key platelet perform research used to assist ticagrelor’s approval had been misreported. Non-significant outcomes had been revealed as important, greater than 60 platelet take a look at outcomes had been lacking from FDA datasets, and a few examine authors denied involvement. These flaws increase critical doubts about whether or not ticagrelor actually affords advantages.
Q: How does this have an effect on me if I’ve been prescribed ticagrelor?
A: In the event you’re on ticagrelor, you must know that its supposed benefits usually are not backed by constant or dependable science. Sufferers within the U.S. — the very inhabitants the place the drug was most closely promoted — truly skilled worse outcomes, together with larger dangers of coronary heart occasions.
Q: What steps can I take to guard myself?
A: You may scale back reliance on flawed medicine by asking about safer, confirmed alternate options, questioning the standard of proof earlier than beginning new prescriptions, reducing your cardiovascular threat via weight loss plan and life-style, monitoring your progress with easy well being instruments, and staying knowledgeable about drug security investigations. These steps maintain your well being choices in your palms as a substitute of within the palms of pharmaceutical firms.
Check Your Information with In the present day’s Quiz!
Take right now’s quiz to see how a lot you’ve discovered from yesterday’s Mercola.com article.
What key perform of the mind do sleep medicine intrude with throughout deep sleep?
